Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus PREMPHASE 14 14.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus PREMPHASE 14 14.
NORGESTIMATE AND ETHINYL ESTRADIOL vs PREMPHASE 14/14
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
Conjugated estrogens (CE) bind to estrogen receptors (ERα and ERβ), modulating gene transcription and non-genomic signaling pathways to induce estrogenic effects. Medroxyprogesterone acetate (MPA) is a progestin that binds to progesterone receptors, suppressing endometrial proliferation and counteracting estrogen-induced endometrial hyperplasia. The combination provides hormone replacement therapy with reduced risk of endometrial cancer.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
One tablet orally once daily, each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg.
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
Conjugated estrogens have a terminal elimination half-life of 12-24 hours for conjugated equine estrogens; medroxyprogesterone acetate has a half-life of 12-17 hours. Steady-state is reached within 5-7 days.
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Conjugated estrogens are excreted primarily in urine (≥90%) as glucuronide and sulfate conjugates; medroxyprogesterone acetate is extensively metabolized and excreted in urine (≤60%) and feces (≤30%) as metabolites.
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination